Want to see CASIF full AI Analyst Report?
CASIF Stock Chart & Stats
$1.06
-$0.35(-10.90%)
At close: 4:00 PM EST
$1.06
-$0.35(-10.90%)
Day’s Range― - ―
52-Week Range$0.05 - $3.09
Previous CloseN/A
VolumeN/A
Average Volume (3M)219.83K
Market Cap
$2.71M
Enterprise Value$17.12M
Total Cash (Recent Filing)$5.63M
Total Debt (Recent Filing)$27.49M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.86
Shares Outstanding20,555,874
10 Day Avg. Volume60,876
30 Day Avg. Volume219,829
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)-0.42
Price to Sales (P/S)0.76
P/FCF Ratio-0.76
Enterprise Value/Market Cap6.32
Enterprise Value/Revenue0.83
Enterprise Value/Gross Profit1.70
Enterprise Value/Ebitda-0.40
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.41
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt ReductionThe sale of the China business to Kaixin allows the company to eliminate $20M of existing debt, improving its financial position.
Product DevelopmentCID-103 has shown superior activity and reduced toxicity compared to existing CD38 inhibitors in preclinical and Phase 1 studies, indicating strong potential for successful development.
Strategic ManagementThe appointment of David Cory as the company’s new CEO, who has more than 30 years of experience in the biotech and pharma sectors, is seen as beneficial for the company’s new direction.
Bears Say
Financial PerformanceCASI reported revenues of $4.2M and a net loss of $0.86 per share for the quarter, which was below the consensus estimated revenue of $6.3M and net loss of $0.47 per share.
Licensing And RevenueThe company received a Termination Process Letter to withdraw the Evomela license following a wind-down period, which impacts the company's Chinese business revenues.
Revenue ImpactThe company reported lower-than-expected revenues, which fell 16% year-over-year, primarily due to increased generic competition for Evomela in China.
CASI Pharmaceuticals News
CASIF FAQ
What was CASI Pharmaceuticals’s price range in the past 12 months?
CASI Pharmaceuticals lowest stock price was $0.05 and its highest was $3.09 in the past 12 months.
What is CASI Pharmaceuticals’s market cap?
CASI Pharmaceuticals’s market cap is $2.71M.
When is CASI Pharmaceuticals’s upcoming earnings report date?
CASI Pharmaceuticals’s upcoming earnings report date is Aug 07, 2026 which is in 28 days.
How were CASI Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is CASI Pharmaceuticals overvalued?
According to Wall Street analysts CASI Pharmaceuticals’s price is currently Overvalued.
Does CASI Pharmaceuticals pay dividends?
CASI Pharmaceuticals does not currently pay dividends.
What is CASI Pharmaceuticals’s EPS estimate?
CASI Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CASI Pharmaceuticals have?
CASI Pharmaceuticals has 20,555,874 shares outstanding.
What happened to CASI Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CASI Pharmaceuticals?
Currently, no hedge funds are holding shares in CASIF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. operates as a biopharmaceutical firm, focusing on the development and commercialization of therapeutic and pharmaceutical products across the People's Republic of China, the United States, and international territories. The company's offerings include EVOMELA, an intravenous formulation of melphalan, which serves as a conditioning treatment before stem cell transplantation and as palliative care for patients with multiple myeloma. Its hematology/oncology pipeline is robust, featuring CNCT19, an investigative autologous CD19 CAR-T product; BI-1206, a novel anti-FcγRIIB antibody designed for treating solid tumors and relapsed/refractory non-Hodgkin lymphoma; CB-5339, an innovative VCP/p97 inhibitor targeting valosin-containing protein (VCP)/p97 pathways crucial for protein homeostasis, DNA damage response, and cellular stress in various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent with diverse indications, including its use as a conditioning regimen prior to certain allogeneic hematopoietic stem cell transplants. CASI Pharmaceuticals maintains licensing agreements with entities such as Juventas Cell Therapy Ltd., BioInvent International AB, Black Belt Therapeutics Limited, Cleave Therapeutics, Inc., and Acrotech Biopharma L.L.C., primarily for the development and commercialization of its commercial product, EVOMELA. The company was founded in 1991 and is headquartered in Beijing, People's Republic of China.
Technical Analysis
Ownership Overview
―
Insiders
5.45% Other Institutional Investors
94.55% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---